tiprankstipranks
Celularity resolves Nasdaq listing compliance issue
PremiumThe FlyCelularity resolves Nasdaq listing compliance issue
1M ago
Celularity raises FY24 revenue view to $54M-$60M from $50M-$56M
Premium
The Fly
Celularity raises FY24 revenue view to $54M-$60M from $50M-$56M
2M ago
Celularity files amended compliance plan with Nasdaq Hearings Panel
Premium
The Fly
Celularity files amended compliance plan with Nasdaq Hearings Panel
2M ago
Celularity sees Q2 net sales of biomaterial product, biobanking $11M-$13M
PremiumThe FlyCelularity sees Q2 net sales of biomaterial product, biobanking $11M-$13M
5M ago
Celularity sees Q1 net sales of biomaterial product, biobanking $14.8M
Premium
The Fly
Celularity sees Q1 net sales of biomaterial product, biobanking $14.8M
5M ago
Celularity reports Q4 combined net sales $12.1M
Premium
The Fly
Celularity reports Q4 combined net sales $12.1M
5M ago
Celularity data showing senescent cell elimination to be presented at ASGCT
PremiumThe FlyCelularity data showing senescent cell elimination to be presented at ASGCT
9M ago
Celularity receives HCPCS Q code approval from U.S. CMS for Biovance 3L
Premium
The Fly
Celularity receives HCPCS Q code approval from U.S. CMS for Biovance 3L
9M ago
Celularity submits request to FDA for orphan drug designation for PDA-002
Premium
The Fly
Celularity submits request to FDA for orphan drug designation for PDA-002
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100